The novel fixed-dose combination Cagrilintide-Semaglutide (CagriSema), merging a GLP-1 receptor agonist (Semaglutide) with an amylin analog (Cagrilintide), represents a significant therapeutic advance
Switching from retatrutide to tirzepatide This direction is simpler because you are removing a receptor pathway rather than adding one: Stop retatrutide and allow 1-2 weeks washout Start tirzepatide at 2.5 mg per standard protocol Escalate normally every 4 weeks Expect potentially faster tolerance since your GLP-1 and GIP receptors already have exposure history Some researchers report smoother GI tolerance when switching from a triple to a dual agonist, which makes pharmacological sense
nothing on this page is a recommendation to use research-grade tirzepatide outside of an FDA-approved indication
Eat a Balanced Diet: Consume a diet rich in fruits, vegetables, whole grains, lean proteins, and healthy fats
However, as long as you create the proper window (2-3 hours after eating), nighttime administration is also perfectly effective